tirzepatide lawsuit in west virginia FDA backtracks over Eli Lilly weight-loss drug shortage CVS, CareFirst BlueCross BlueShield hit

The markings on the barrel read in units, typically going from 0 to 100 in increments of 1 or 2

There is no guarantee of treatment upon scheduling either appointment

4.4 SURPASS-4 trial comparison of tirzepatide and insulin glargine The SURPASS-4 trial included 1,995 patients with type 2 diabetes and compared tirzepatide (5 mg, 10 mg, 15 mg) with insulin glargine over 52 weeks, with the primary endpoint being the change in HbA1c (Heerspink et al., 2022)

For many patients, weekly injections are generally considered the more traditional and evidence-supported route for GLP-1 weight management

To read more verified patient experiences and success stories, learn more about Brello Health benefits

The main difference is receptor targeting